Med24
Clinical Medicine 2. 10. 2026 • 2 min read • medical-news

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

The FDA on Friday expanded the approval of pirtobrutinib (Jaypirca) in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) to include the first-line treatment of adults whose cancers have no known 17p deletion...

Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia

The FDA has expanded the approval of pirtobrutinib for the first-line treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who do not have a known 17p deletion. This approval is based on results from the randomized BRUIN-CLL-313 trial, which demonstrated a 80% reduction in the risk of disease progression or death compared to chemoimmunotherapy. Median progression-free survival was not estimable in the pirtobrutinib arm. The overall response rate reached 94% with pirtobrutinib versus 81% with bendamustine plus rituximab. Doctors can now consider pirtobrutinib for appropriate patients when initial therapy is needed. Pirtobrutinib was first approved for pretreated CLL/SLL and has shown activity in patients with Richter transformation and mantle cell lymphoma. The BRUIN-CLL-313 trial also demonstrated consistent safety and tolerability. Common non-laboratory adverse events included upper respiratory tract infections, rash, and COVID-19. Common grade 3/4 laboratory abnormalities included decreased neutrophil counts. Serious adverse events occurred in 28% of patients, with warnings and precautions including infections, hemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity, and embryo-fetal toxicity.

Sponsored content

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement